conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Please note NiYondashay is a COSENTYX ® (secukinumab) patient and has been compensated for her time. Continue reading for ...